comparemela.com

Latest Breaking News On - Eyepoint pharmaceuticals trading - Page 1 : comparemela.com

EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $38.00 by Analysts at Robert W. Baird

EyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $38.00 by Analysts at Robert W. Baird
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

China
Robertw-baird
China-universal-asset-management-co
Investment-advisers
Nasdaq
Jpmorgan-chase-co
Analyst-recommendations-for-eyepoint-pharmaceuticals
Eyepoint-pharmaceuticals-inc
Eyepoint-pharmaceuticals-trading
Tower-research-capital
Eyepoint-pharmaceuticals-company-profile

EyePoint Pharmaceuticals (NASDAQ:EYPT) PT Lowered to $38.00

EyePoint Pharmaceuticals (NASDAQ:EYPT) PT Lowered to $38.00
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

China
Robertw-baird
Tower-research-capital
Eyepoint-pharmaceuticals-trading
Eyepoint-pharmaceuticals-inc
Analyst-recommendations-for-eyepoint-pharmaceuticals
Jpmorgan-chase-co
Institutional-trading-of-eyepoint-pharmaceuticals
Eyepoint-pharmaceuticals
Toth-financial-advisory-corp
News-ratings-for-eyepoint-pharmaceuticals-daily

Insider Selling: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Insider Sells 49,325 Shares of Stock

Insider Selling: EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Insider Sells 49,325 Shares of Stock
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

China
Darioa-paggiarino
News-ratings-for-eyepoint-pharmaceuticals-daily
Lazard-asset-management
Jpmorgan-chase-co
Quarter-for-eyepoint-pharmaceuticals
Nasdaq
Eyepoint-pharmaceuticals-inc
Institutional-trading-of-eyepoint-pharmaceuticals
China-universal-asset-management-co
Investment-advisers

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Major Shareholder Sells $2,036,273.60 in Stock

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) major shareholder Ew Healthcare Partners, L.P. sold 139,280 shares of EyePoint Pharmaceuticals stock in a transaction that occurred on Thursday, August 24th. The shares were sold at an average price of $14.62, for a total transaction of $2,036,273.60. Following the sale, the insider now owns 3,883,760 shares […]

United-kingdom
United-states
China
Tower-research-capital
Schonfeld-strategic-advisors
Cubist-systematic-strategies
Eyepoint-pharmaceuticals-trading
Eyepoint-pharmaceuticals-inc
Barclays-plc
Securities-exchange-commission
Nasdaq

EyePoint Pharmaceuticals (NASDAQ:EYPT) Upgraded to Hold at StockNews.com

StockNews.com upgraded shares of EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) from a sell rating to a hold rating in a report published on Friday. A number of other research firms also recently weighed in on EYPT. Chardan Capital reissued a buy rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a […]

United-states
United-kingdom
China
Robertw-baird
Eyepoint-pharmaceuticals-trading
Vontobel-holding-ltd
Eyepoint-pharmaceuticals-company-profile
Schonfeld-strategic-advisors
News-ratings-for-eyepoint-pharmaceuticals-daily
Tower-research-capital
Cubist-systematic-strategies

vimarsana © 2020. All Rights Reserved.